Pharmaceutical · Fiscal year end Dec 31

TAIKO PHARMACEUTICAL CO., LTD.

4574

大幸薬品株式会社

FIGI BBG000DPW4P84574.T4574 JPCorp. no. 2120901007344

Latest half-year results

First half · fiscal year to 2026-12 · filed 2026-08-13

For the first half of the fiscal year to 2026-12: Revenue ¥2.6 billion (+9.3% YoY), Ordinary income ¥0 billion (+105.0% YoY), Net income ¥0 billion (-84.2% YoY).

	This period	Year on year
Revenue	¥2.6bn	+9.3%
Ordinary profit	¥41m	+105.0%
Net profit to owners	¥44m	-84.2%

From the securities report on EDINET, which states no forecast. History via /v1/companies/4574/earnings-releases.

Financials

Japan GAAP · consolidated · fiscal year to 2025-12-31

Revenue: ¥6.4bn
Net income: ¥923m
ROE: 11.2%
Equity ratio: 69.4%
Dividend / share: ¥3.3
Employees: 220

Revenue · ¥bn

Net income · ¥bn

Fiscal year	Revenue	Net income	Total assets	Net assets	ROE	EPS	Operating CF
2025-12-31	¥6.4bn	¥0.9bn	¥12.3bn	¥8.5bn	11.2%	¥18.38	¥0.8bn
2024-12-31	¥6.3bn	¥0.9bn	¥12.9bn	¥8.0bn	12.2%	¥17.9	¥0.4bn
2023-12-31	¥6.1bn	−¥3.6bn	¥13.2bn	¥6.7bn	-48.9%	¥-76.25	−¥0.3bn
2022-12-31	¥5.0bn	−¥4.9bn	¥15.0bn	¥8.0bn	-47.0%	¥-112.26	−¥2.0bn
2021-12-31	¥11.3bn	−¥9.6bn	¥22.5bn	¥12.8bn	-53.9%	¥-220.52	−¥1.6bn

Indicators

Computed by us from filings · fiscal year to 2025-12-31

Metric	Value	Percentile among listed companies
ROE, %	11.2	64.5
Ordinary margin	0.0753	54.3
Equity ratio, %	69.4	73.7
Revenue growth	0.0167	32.5
Net income growth	0.0278	38.5
Operating cash flow / assets	0.0663	51.6

Policy-uncertainty measure0.90 Share of the report's text discussing policy-related uncertainty, by policy area. Proprietary text method.

Trade & tariffs 1

Ownership activity 0 filer(s) stated they may make proposals in 365 days; 0 new 5% holder(s) in 180 days; net stake change 0.00pt in 90 days; 2.6% held by other listed companies.

Results wording balance: +1.00. Proprietary text method; it describes the wording only and does not interpret context.

Interest example: if all ¥792m of reported debt repriced by 50 basis points, a year's interest would rise by ¥4m, 0.5% of operating cash flow. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.

Via /v1/companies/4574/indicators. Descriptive figures, not a rating and not investment advice.

From other filings

As the company states them

Internal control, 2026-03-24: see filing 上記の評価の結果、当事業年度末日時点において、当社の財務報告に係る内部統制は有効であると判断いたしました。 Filing

Segments, votes and tender offers

Stated in EDINET filings

Segments: Pharmaceuticals Business, Infection Control Business, Other. /v1/companies/4574/segments

Latest voting result: 2026-03-27 · 剰余金処分の件 · passed. /v1/companies/4574/voting

Ownership changes

All companies →

2023-10-20

Below 5%−1.29pt

Nomura Securities Co.,Ltd. cut holdings in TAIKO PHARMACEUTICAL CO., LTD. (4574) to 4.02% from 5.31%, below the 5% threshold.

S100S1ZXFiler profile Original filing (PDF, Japanese)
2023-08-22

Decrease−1.95pt

Nomura Securities Co.,Ltd. reduced holdings in TAIKO PHARMACEUTICAL CO., LTD. (4574) to 5.31% from 7.26%.

S100RQNNFiler profile Original filing (PDF, Japanese)
2023-08-18

Amendment0.00pt

Kingworld Medicines Health Management Limited filed a correction to a 5% report on TAIKO PHARMACEUTICAL CO., LTD. (4574).

S100RQ8GFiler profile Original filing (PDF, Japanese)
2023-08-17

New 5% stake

Kingworld Medicines Health Management Limited disclosed a 6.42% stake in TAIKO PHARMACEUTICAL CO., LTD. (4574), crossing the 5% reporting threshold.

S100RF9AFiler profile Original filing (PDF, Japanese)
2023-08-17

Amendment0.00pt

Kingworld Medicines Health Management Limited filed a correction to a 5% report on TAIKO PHARMACEUTICAL CO., LTD. (4574).

S100RQ56Filer profile Original filing (PDF, Japanese)
2023-07-06

Decrease−2.07pt

Nomura Securities Co.,Ltd. reduced holdings in TAIKO PHARMACEUTICAL CO., LTD. (4574) to 7.26% from 9.33%.

S100RC5AFiler profile Original filing (PDF, Japanese)
2023-06-09

Decrease−0.87pt

Nomura Securities Co.,Ltd. reduced holdings in TAIKO PHARMACEUTICAL CO., LTD. (4574) to 9.33% from 10.20%.

S100QX4PFiler profile Original filing (PDF, Japanese)
2023-06-09

Threshold

Holdings of Nomura Securities Co.,Ltd. in TAIKO PHARMACEUTICAL CO., LTD. (4574) moved below 10% (10.20% -> 9.33%).

S100QX4PFiler profile Original filing (PDF, Japanese)
2023-05-29

Decrease−1.18pt

Nomura Securities Co.,Ltd. reduced holdings in TAIKO PHARMACEUTICAL CO., LTD. (4574) to 10.20% from 11.38%.

S100QULEFiler profile Original filing (PDF, Japanese)
2023-04-28

Decrease−4.34pt

Nomura Securities Co.,Ltd. reduced holdings in TAIKO PHARMACEUTICAL CO., LTD. (4574) to 11.38% from 15.72%.

S100QO8PFiler profile Original filing (PDF, Japanese)

Trades by 5% holders

From the 60-day trade tables in 5% reports

Bought SoldHover a dot for the trade

Holder	Period	Net shares	Net % of shares	Avg. filed price	Range
NOMURA INTERNATIONAL PLC	2023-01-20 – 2023-06-05	+58,900	+0.23pt	¥388.84	¥360–431
野村アセットマネジメント株式会社	2023-01-20 – 2023-06-05	+73,800	+0.15pt	¥380.51	¥361–429
野村證券株式会社	2023-01-20 – 2023-06-05	+2,964,400	+5.83pt	¥380.59	¥361–412
individual filer	2023-05-23 – 2023-05-23	0	0.00pt	—	—
アース製薬株式会社	2022-10-03 – 2022-10-24	-289,800	−0.60pt	—	—

Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4574/trades.

5% filings

Large shareholding reports on 4574

Filed	Filer	Stake	Change	Stated purpose
2023-10-20	Nomura Securities Co.,Ltd.	4.02%	−1.29pt	—
2023-08-22	Nomura Securities Co.,Ltd.	5.31%	−1.95pt	—
2023-08-18	Kingworld Medicines Health Management Limited	6.42%	—	strategic holding
2023-08-17	Kingworld Medicines Health Management Limited	6.42%	—	strategic holding
2023-08-17	Kingworld Medicines Health Management Limited	6.42%	—	strategic holding
2023-07-06	Nomura Securities Co.,Ltd.	7.26%	−2.07pt	—
2023-06-09	Nomura Securities Co.,Ltd.	9.33%	−0.87pt	—
2023-05-29	Nomura Securities Co.,Ltd.	10.20%	−1.18pt	—
2023-04-28	Nomura Securities Co.,Ltd.	11.38%	−4.34pt	—
2023-04-26	Nomura Securities Co.,Ltd.	15.72%	−1.16pt	—

Cross-shareholdings

From the annual report's status of shareholdings

Listed strategic holdings: — issues
Book value: —
Sold in the year: — — issues
Bought in the year: — — issues
Mutual, both reports: 0
Held by listed cos.: 1

Holds	Book value	Shares vs. prior year	Mutual
Cuorips Inc. 4894	—	sold all	no

Held by: Earth Corporation 4985

Purposes, all holdings and mutual flags via /v1/companies/4574/cross-holdings. Share changes include stock splits.

Major shareholders

As of fiscal year end 2025-12-31

Shareholder	Shares	Ratio
ROYAL BANK OF CANADA SINGAPORE BRANCH-CLIENT’S A/C	3,852,765	7.67%
日本マスタートラスト信託銀行株式会社（信託口）	3,426,100	6.82%
individual holder	3,330,431	6.63%
individual holder	3,298,810	6.56%
individual holder	3,185,900	6.34%
individual holder	2,129,400	4.24%
individual holder	1,899,445	3.78%
興和株式会社	1,508,000	3.00%
individual holder	1,336,054	2.66%
アース製薬株式会社	1,311,400	2.61%

Get this as JSON

GET /v1/companies/4574
GET /v1/companies/4574/financials
GET /v1/companies/4574/details
GET /v1/companies/4574/segments
GET /v1/companies/4574/voting
GET /v1/companies/4574/tender-offers
GET /v1/companies/4574/indicators
GET /v1/companies/4574/earnings-releases
GET /v1/events?ticker=4574
GET /v1/companies/4574/trades         
GET /v1/companies/4574/cross-holdings 
GET /v1/companies/4574/brief

Plans from $9 a month · Documentation